ABUS - Arbutus Biopharma Corp
IEX Last Trade
3.17
-0.950 -29.968%
Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:59 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$4.12
-0.95
-23.06%
Fundamental analysis
25%
Profitability
25%
Dept financing
7%
Liquidity
75%
Performance
18%
Performance
5 Days
-0.93%
1 Month
-7.02%
3 Months
-18.67%
6 Months
4.26%
1 Year
34.18%
2 Year
36.48%
Key data
Stock price
$3.17
DAY RANGE
$3.15 - $4.12
52 WEEK RANGE
$2.27 - $4.72
52 WEEK CHANGE
$28.23
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: William H. Collier
Region: US
Website: arbutusbio.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: arbutusbio.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Arbutus Biopharma Corporation develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate. AB-836, an oral capsid inhibitor that suppresses HBV DNA replication, is in Phase Ia/Ib clinical trial targeted to hepatocytes.
Recent news